#Hong Kong #Gilead Sciences #Encequidar #Health Hope Pharma

Health Hope Pharma Partners with Gilead Sciences

In a groundbreaking move, Health Hope Pharma Limited (HHP) has announced a global licensing and collaboration agreement with Gilead Sciences, Inc. This strategic alliance focuses on encequidar, a pioneering P-glycoprotein inhibitor that holds promise in the field of virology. This collaboration signifies a major milestone in biopharmaceutical innovation, particularly for HHP, a company headquartered in Hong Kong.

The Core of the Agreement

Under the terms of the agreement, HHP, alongside its partner Hanmi Pharm, will grant Gilead exclusive global rights to encequidar for virology applications. Additionally, HHP will provide Gilead with access to drug supplies and share vital technical expertise as two key project collaborators. The deal includes upfront payments and provisions for developmental, regulatory, and commercial milestones, along with low single-digit royalties on net sales.

Prof. Dennis Lam, the founder of HHP, expressed excitement about the partnership, stating that this agreement underscores the potential for encequidar as a key player in developing new oral formulations across various medical fields. He highlighted that HHP aims to accelerate the development of oral paclitaxel in concert with encequidar, setting their sights on initiating a global Phase III clinical study for this treatment in both the U.S. and Hong Kong SAR by the end of 2025.

Innovation in Oncology

The most advanced project for HHP involves a combination therapy aiming to transition from intravenous to oral administration of paclitaxel, which is primarily used for chemotherapy in metastatic breast cancer. This could significantly enhance patient quality of life by providing a safer and more convenient therapy option. Health Hope Pharma aims to enroll the first patients for this innovative treatment by the fourth quarter of 2025, marking a crucial step in enhancing chemotherapeutic options.

The Future of Health Hope Pharma

As HHP pushes boundaries in oncology, it prepares for extensive global clinical trials, including sites in the U.S., Hong Kong SAR, and New Zealand. Their ambition also includes a rollout plan for the product across Europe and Asia, as well as the U.S. market.

Jae-Hyun Park, CEO of Hanmi, commented on the partnership's validation of Hanmi's formulation technology. He reiterated a commitment to expanding collaborative efforts that foster innovation and improve patient access globally.

About Health Hope Pharma

Health Hope Pharma is dedicated to revolutionizing cancer treatment with novel oral drugs. Their primary focus, oral paclitaxel in combination with encequidar, aims to challenge the conventional intravenous methods, ultimately benefiting patients through a more flexible treatment regimen. Additionally, HHP emphasizes research and continuous improvement within the oncology biotech sector, making strides toward a future where oral therapies become standard practice.

About Hanmi Pharm

Hanmi Pharm, known for its innovation-focused approach, is committed to developing therapies in oncology, metabolism, and rare disease treatments. With proprietary technologies in biologics and antibodies, the company seeks to address significant unmet medical needs. Through open innovation and global partnerships, Hanmi continues to advance its research efforts in the biopharmaceutical domain.

By solidifying its collaboration with Gilead Sciences, Health Hope Pharma not only enhances its development portfolio but also makes a significant contribution to the biotech landscape in Hong Kong and beyond.